Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Nektar Therapeutics (NASDAQ:NKTR) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $4.08.

NKTR has been the subject of a number of recent analyst reports. B. Riley initiated coverage on shares of Nektar Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $4.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $6.50 price target on shares of Nektar Therapeutics in a research note on Monday, January 13th. Piper Sandler started coverage on Nektar Therapeutics in a research report on Monday, November 4th. They set an “overweight” rating and a $7.00 price objective for the company. Finally, BTIG Research reaffirmed a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th.

Nektar Therapeutics Trading Up 0.0 %

Shares of NKTR opened at $0.89 on Tuesday. Nektar Therapeutics has a 12-month low of $0.48 and a 12-month high of $1.93. The firm has a market capitalization of $164.54 million, a P/E ratio of -1.06 and a beta of 0.59. The firm has a 50-day moving average price of $1.03 and a 200 day moving average price of $1.20.

Insiders Place Their Bets

In other Nektar Therapeutics news, insider Mark Andrew Wilson sold 33,402 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.90, for a total value of $30,061.80. Following the completion of the transaction, the insider now owns 351,892 shares in the company, valued at $316,702.80. The trade was a 8.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Howard W. Robin sold 46,995 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total value of $47,464.95. Following the completion of the sale, the chief executive officer now owns 1,195,710 shares in the company, valued at approximately $1,207,667.10. The trade was a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 155,575 shares of company stock worth $149,878 over the last three months. Company insiders own 3.71% of the company’s stock.

Institutional Investors Weigh In On Nektar Therapeutics

Several large investors have recently bought and sold shares of NKTR. Victory Capital Management Inc. purchased a new position in shares of Nektar Therapeutics in the 2nd quarter valued at about $29,000. Valence8 US LP acquired a new stake in Nektar Therapeutics in the third quarter valued at approximately $34,000. Intech Investment Management LLC acquired a new position in Nektar Therapeutics during the 3rd quarter worth approximately $41,000. XTX Topco Ltd purchased a new stake in shares of Nektar Therapeutics in the 3rd quarter valued at approximately $46,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of Nektar Therapeutics in the 3rd quarter valued at $61,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.